HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Not To Do When An FDA Inspector Knocks At Your Door

This article was originally published in The Tan Sheet

Executive Summary

FDA tweaks its guidance on what constitutes interference with inspections to include examples of “reasonable” explanations for delays. But industry requested other changes, including a formal process for notifying a firm of FDA’s intent to deem products adulterated due to delaying, limiting or refusing an inspection.

You may also be interested in...



Rx Companies Push For Exemptions To Breadth Of FDA Inspections

Sterile areas, cell therapies, and security systems are just a few of the items where industry wants FDA inspector access limited without triggering a new law that would make products in a facility deemed adulterated.

She Didn’t Need To Be Commissioner: Janet Woodcock’s Transformative Legacy

She is as polarizing as she is powerful, but whether you think Janet Woodcock is drug development’s hero or public health’s enemy, there’s no denying she dramatically transformed the US FDA over her 35-year career.

Washington State To Restrict Phthalates In Fragrance; Alternatives ‘Feasible And Available’

Personal-care and beauty products can do without fragrances that contain phthalates, says Washington Department of Ecology in a November Draft Regulatory Determinations Report to state lawmakers as per the Safer Products for Washington Act. Restriction specifics will be worked out in 2022 in consultation with stakeholders, Ecology says.

Topics

Related Companies

UsernamePublicRestriction

Register

RS139586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel